Renalytix AI PLC - diagnostics company - Notes that KidneyIntelX may be widely adopted by primary care physicians and could help improve care for patients at high risk for progressive kidney function decline or failure.
"Clear and objective utility evidence like these results presented at the National Kidney Foundation Spring Clinical Meeting this week are critical for evaluating the value of innovative new approaches for chronic kidney disease assessment," said Elizabeth Montgomery, vice-president of Learning Strategies & Primary Care Programs at the National Kidney Foundation.
Current stock price: 900.00 pence, down 3.2% on Thursday
Year-to-date change: up 85%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Renalytix Plc (RENX)